High sensitivity
point-of-care
molecular diagnostics
ZiP Diagnostics undertakes domestic manufacture of cutting-edge point-of-care molecular diagnostic test systems for infectious diseases.
ZiP systems provide the advantage of portable diagnostics that can be quickly deployed to deliver fast, accurate, low-cost and easy-to-use on-site testing.
ZiP is developing test systems for chlamydia and gonorrhoea, in low to middle-income countries and a SARS-CoV-2 (COVID-19) diagnostic for Australian domestic applications.The ZiP-CoVx diagnostic test is intended for use in a broad range of settings, including: government, health, travel, defence, education, mining, industry, and sport.
NEWS
ZiP Diagnostics secures $600,000 federal grant for COVID-19 test
Federal Minister for Health, the Hon Greg Hunt, made the announcement today, revealing details of the third round of grants from the $45 million BioMedTech Horizons (BMTH) program.
“We are delighted to receive this BMTH grant as it provides valuable funding for the development of ZiP’s technology and will allow us to secure regulatory approval in a shorter time frame than originally envisaged,” said ZiP Technical Director Bill Hopper.
All key elements of the ZiP technology are made locally ensuring Australia is less susceptible to global supply chain issues for diagnostic equipment. The test regime is suitable for use across many industry and community sectors including government, health, travel, defence, education, mining, industrial, commercial and sport.
“This innovative technology and our local production capacity means ZiP is ideally placed to play a major role in the identification, containment and management of COVID-19 in Australia,” Mr Hopper said.
19th July 2020